[ Pobierz całość w formacie PDF ]

40. Massard C, Teutsch E, Soria JC. Tumour stem cell-targeted treatment: 68. Yin C, Lin Y, Zhang X i wsp. Differentiation therapy of hepatocellular
elimination or differentiation. Ann Oncol 2006; 17: 1620-4. carcinoma in mice with recombinant adenovirus carrying hepatocyte
41. Jin L, Hope KJ, Zhai Q i wsp. Targeting of CD44 eradicates human acute nuclear factor-4alpha gene. Hepatology 2008; 48: 1528-1539
myeloid leukemic stem cells. Natural Medicine 2006; 12: 1167-1174. 69. Andreas G. Schätzlein. Delivering cancer stem cell therapies  A role for
42. Lee J, Son MJ, Woolard K i wsp. Epigenetic-mediated dysfunction of nanomedicines? Eur J Cancer 2006; 42: 1309-15.
the bone morphogenetic protein pathway inhibits differentiation of 70. Minko T, Kopeckova P, Pozharov V i wsp. HPMA copolymer bound
glioblastoma-initiating cells. Cancer Cell 2008; 13: 69-80. adriamycin overcomes MDR1 gene encoded resistance in a human
43. Bourguignon LY, Peyrollier K, Xia W i wsp. Hyaluronan-CD44 ovarian carcinoma cell line. J Control Release 1998; 54: 223-33.
interaction activates stem cell marker Nanog, Stat-3-mediated MDR1 71. Duncan R. The dawning era of polymer therapeutics. Nat Rev Drug
gene expression, and ankyrin-regulated multidrug efflux in breast and Discov 2003; 2: 347-60.
72. Kabanov AV, Batrakova EV, Alakhov VY. An essential relationship
ovarian tumor cells. J Biol Chem 2008; 283: 17635-51.
44. Dylla SJ, Beviglia L, Park IK i wsp. Colorectal Cancer Stem Cells Are between ATP depletion and chemosensitizing activity of Pluronic block
Enriched in Xenogeneic Tumors Following Chemotherapy. PLoS ONE. copolymers. J Control Release 2003; 91: 75-83.
73. Kabanov AV, Batrakova EV, Alakhov VY. Pluronic block copolymers
2008; 18; 3: e2428
45. Beier D, Röhrl S, Pillai DR i wsp. Temozolomide Preferentially Depletes for overcoming drug resistance in cancer. Adv Drug Deliv Rev 2002; 54:
Cancer Stem Cells in Glioblastoma. Cancer Res 2008; 68: 5706-15. 759-79.
46. Liu G, Yuan X, Zeng Z i wsp. Analysis of gene expression and 74. Venne A, Li S, Mandeville R i wsp. Hypersensitizing effect of pluronic
chemoresistance of CD133+ cancer stem cells in glioblastoma. Mol L61 on cytotoxic activity, transport, and subcellular distribution of
Cancer 2006; 2;5:67. doxorubicin in multiple drug-resistant cells. Cancer Res 1996; 56: 3626-
47. Yilmaz OH, Valdez R, Theisen BK i wsp. Pten dependence distinguishes 9.
haematopoietic stem cells from leukaemia-initiating cells. Nature 2006; 75. Tokes ZA, Rogers KE, Rembaum A. Synthesis of adriamycin coupled
441: 475-82. polyglutaraldehyde microspheres and evaluation of their cytostatic
48. Kawasaki BT, Farrar WL. Co-expression of the toleragenic glycoprotein, activity. Proc Natl Acad Sci 1982; 79: 2026-30.
CD200, with markers for cancer stem cells. Biochem Biophys Res 76. Larsen AK, Escargueil AE, Skladanowski A. Resistance mechanisms
Commun 2007; 364: 778-82 associated with altered intracellular distribution of anticancer agents.
49. Halama N, Zoernig I, Jäger D. Immunotherapy for cancer modern Pharmacol Ther 2000; 85: 217-29.
immunologic strategies in oncology. Dtsch Med Wochenschr 2008; 133: 77. Dean M, Fojo T, Bates S. Tumour stem cells and drug resistance. Nat Rev
2105-8. Cancer 2005; 5: 275-84.
50. Duan W, Ding H, Subler MA i wsp. Lung-specific expression of
human mutant p53-273H is associated with a high frequency of lung
Orzymano: 10 lutego 2009 r.
adenocarcinoma in transgenic mice. Oncogene 2002; 21: 7831-8.
Przyjęto do druku: 5 marca 2009 r.
51. Chen L, Shen R, Ye Y i wsp. Precancerous stem cells have the potential
for both benign and malignant differentiation. PLoS ONE. 2007; 3:
1-16.
52. Spisek R, Kukreja A, Chen LC i wsp. Frequent and specificimmunity
to the embryonal stem cell-associated antigen SOX2 in patients with
monoclonal gammopathy. J Exp Med 2007; 204: 831-40.
53. Ramirez-Castillejo C, Sanchez-Sanchez F, Andreu-Agullo C i wsp. Nat
Neurosci 2006; 9: 331-9.
54. Shen Q, Goderie SK, Jin L i wsp. Endothelial cells stimulate self-renewal
and expand neurogenesis of neural stem cells. Science 2004; 304: 1338-
40.
55. Yang ZJ, Wechsler-Reya RJ. Hit  Em Where They Live: Targeting the
Cancer Stem Cell Niche. Cancer Cell 2007; 11: 3-5.
56. Calabrese C, Poppleton H, Kocak M i wsp. A perivascular niche for brain
tumor stem cells. Cancer Cell 2007; 11: 69-82.
57. Vredenburgh JJ, Desjardins A, Herndon JE i wsp. Phase II trial of
bevacizumab and irinotecan in recurrent malignant glioma. Clin Cancer
Res 2007; 13: 1253-9.
58. Bao Wu Q, Sathornsumetee S i wsp. Stem cell-like glioma cells promote
tumor angiogenesis through vascular endothelial growth factor. Cancer
Res 2006; 66: 7843-8.
59. Malecki M, Jastrzębski Z, Przybyszewska M i wsp. Antiangiogenic gene
therapy: application of soluble FLT-1 receptor. Adv Clin Exp Med 2004;
13: 227-33
60. Jain RK. Normalizing tumor vasculature with anti-angiogenic therapy:
a new paradigm for combination therapy. Natural Medicine 2001; 7:
987-9.
61. Lin MI, Sessa WC. Antiangiogenic therapy: creating a unique  window
of opportunity. Cancer Cell 2004; 6: 529-31.
62. Tozer GM, Kanthou C, Baguley BC. Disrupting tumour blood vessels.
Nat Rev Cancer 2005; 5: 423-35.
63. Folkins C, Man S, Xu P i wsp. Anticancer Therapies Combining
Antiangiogenic and Tumor Cell Cytotoxic Effects Reduce the Tumor
Stem-Like Cell Fraction in Glioma Xenograft Tumors. Cancer Res 2007;
67: 3560-4.
64. Lee CG, Heijn M, di Tomaso E i wsp. Antivascular endothelial growth
factor treatment augments tumor radiation response under normoxic or
hypoxic conditions. Cancer Res 2000; 60: 5565-70.
65. Hess C, Vuong V, Hegyi I i wsp. Effect of VEGF receptor inhibitor
PTK787/ZK222584 [correction of ZK222548] combined with ionizing [ Pobierz całość w formacie PDF ]

zanotowane.pl

doc.pisz.pl

pdf.pisz.pl

ssaver.htw.pl